DE1813275C3 - Molecular compounds from 1-phenyl-2,3-dimethyl-4- (aminoethanesulfonylamino) -pyrazolon-5 and barbituric acids - Google Patents
Molecular compounds from 1-phenyl-2,3-dimethyl-4- (aminoethanesulfonylamino) -pyrazolon-5 and barbituric acidsInfo
- Publication number
- DE1813275C3 DE1813275C3 DE19681813275 DE1813275A DE1813275C3 DE 1813275 C3 DE1813275 C3 DE 1813275C3 DE 19681813275 DE19681813275 DE 19681813275 DE 1813275 A DE1813275 A DE 1813275A DE 1813275 C3 DE1813275 C3 DE 1813275C3
- Authority
- DE
- Germany
- Prior art keywords
- phenyl
- dimethyl
- molecular compounds
- barbituric acid
- aminoethanesulfonylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 title claims description 18
- 150000007656 barbituric acids Chemical class 0.000 title claims description 5
- -1 aminoethanesulfonylamino Chemical group 0.000 title claims description 4
- HNYOPLTXPVRDBG-UHFFFAOYSA-N Barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000000875 corresponding Effects 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N Barbital Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 6
- FDQGNLOWMMVRQL-UHFFFAOYSA-N Diadol Chemical compound C=CCC1(CC=C)C(=O)NC(=O)NC1=O FDQGNLOWMMVRQL-UHFFFAOYSA-N 0.000 description 5
- 229960002319 Barbital Drugs 0.000 description 4
- WTYGAUXICFETTC-UHFFFAOYSA-N Cyclobarbital Chemical compound C=1CCCCC=1C1(CC)C(=O)NC(=O)NC1=O WTYGAUXICFETTC-UHFFFAOYSA-N 0.000 description 4
- 230000000202 analgesic Effects 0.000 description 4
- 229960000880 allobarbital Drugs 0.000 description 3
- 229960004138 cyclobarbital Drugs 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- VIROVYVQCGLCII-UHFFFAOYSA-N Amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- UORJNBVJVRLXMQ-UHFFFAOYSA-N Aprobarbital Chemical compound C=CCC1(C(C)C)C(=O)NC(=O)NC1=O UORJNBVJVRLXMQ-UHFFFAOYSA-N 0.000 description 2
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Dimethyl N aminoantipyrine Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 2
- ALARQZQTBTVLJV-UHFFFAOYSA-N Methylphenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960000212 aminophenazone Drugs 0.000 description 2
- 230000001754 anti-pyretic Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- KQPKPCNLIDLUMF-MRVPVSSYSA-N 5-[(2R)-pentan-2-yl]-5-prop-2-enyl-1,3-diazinane-2,4,6-trione Chemical compound CCC[C@@H](C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-MRVPVSSYSA-N 0.000 description 1
- 229960001301 Amobarbital Drugs 0.000 description 1
- ZRIHAIZYIMGOAB-UHFFFAOYSA-N Butabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=O)NC1=O ZRIHAIZYIMGOAB-UHFFFAOYSA-N 0.000 description 1
- 229940041659 Mephobarbital Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960002695 Phenobarbital Drugs 0.000 description 1
- 229950008243 Secbutabarbital Drugs 0.000 description 1
- 229960003080 Taurine Drugs 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 229960001167 Vinbarbital Drugs 0.000 description 1
- RAFOHKSPUDGZPR-VOTSOKGWSA-N Vinbarbital Chemical compound CC\C=C(/C)C1(CC)C(=O)NC(=O)NC1=O RAFOHKSPUDGZPR-VOTSOKGWSA-N 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229960003153 aprobarbital Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940015694 butabarbital Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960001703 methylphenobarbital Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960002060 secobarbital Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
Description
Die Erfindung betrifft die Molekülverbindungen •us 2 Mol l-Phenyl-2,3-dirnethyl-4-(aminoäthan- »ulfonylamino)-pyrazolon-5(I) und einem Mol einer Barbitursäure, die man durch die Reaktion von I mit Barbitursäuren erhält.The invention relates to the molecular compounds • us 2 mol of l-phenyl-2,3-dirnethyl-4- (aminoethane »Ulfonylamino) -pyrazolon-5 (I) and one mole of a barbituric acid, which can be obtained by the reaction of I with Preserves barbituric acids.
Mole von I Barbilale und ihre MoleI Barbilale pier and its pier
H,N -CH, - CH, -SO, —NH, N -CH, -CH, -SO, -N
N (I)N (I)
O N CH3 ON CH 3
I, das als Ausgangsstoff verwandt wird, ist bisher unveröffentlicht und daher eine neuartige Verbindung, die z. a durch Hydrolyse von l-Phenyl-2,3-dimethyl-4-(acylaminoäthansulfonylamino)-pyrazolon-5 hergestellt werden kann. I enthält die strukturellen Merkinaledesl-Phenyl-l.S-dimethyl-^amino-pyrazolons-S, das eine analgetische Wirkung hat, und des Taurins, einer essentiellen Aminosäure mit oberflächenaktiver Wirkung. Die Verbindung der Formel I ist als sehr stabiles, wasserlösliches Analgeticum bzw. Antipyreticum mit sehr geringer Toxizität verwendbar. Auch die erfindungsgemäßen Molekülverbindungen zeigen !hervorragende analgetische bzw. antipyretische Wirkungen. I, which is used as a starting material, has not yet been published and is therefore a novel compound, the z. a by hydrolysis of l-phenyl-2,3-dimethyl-4- (acylaminoethanesulfonylamino) -pyrazolone-5 can be produced. I contains the structural Merkinaledesl-Phenyl-l.S-dimethyl- ^ amino-pyrazolons-S, which has an analgesic effect, and taurine, an essential amino acid with surface-active properties Effect. The compound of the formula I is available as a very stable, water-soluble analgesic or antipyretic usable with very low toxicity. The molecular compounds according to the invention also show ! excellent analgesic and antipyretic effects.
Die erfindungsgemäß verwandten Barbitursäuren sind ?.. B. Barbital (5,5-Diäthylbarbitursäure), AlIobarbital (5,5-Diallylbarbitursäure), Cyclobarbital (5-[1-Cyclohexenyl] - 5 - äthyl - barbitursäure), Phenobarbital (5 - Äthyl - 5 - phenylbarbitursäure), Aprobarbital (5 - Allyl - 5 - isopropylbarbitursäure), Amobarbital (5 - Äthyl - 5 - isoamylbarbitursäure), Pentobarbital (5-Äthyl-5-[l -methylbutyl]-barbitursäure), Secobarbital (5 - Ally 1 - 5 - [ 1 - methylbutyl] - barbitursäure), Vinbarbital (5-Äthyl-5-[l-methyl- 1-butenyl]-barbitursäure), Butabarbital (S-Äthyl-S-sec.-butylbarbitursäure) und Mephobarbital (5-Äthyl-1 -methyl-5-phenylbarbitursäure). The barbituric acids used according to the invention are? .. B. barbital (5,5-diethylbarbituric acid), aliobarbital (5,5-diallylbarbituric acid), cyclobarbital (5- [1-cyclohexenyl] -5-ethyl-barbituric acid), phenobarbital (5-ethyl - 5 - phenylbarbituric acid), aprobarbital (5 - allyl - 5 - isopropylbarbituric acid), amobarbital (5 - ethyl - 5 - isoamylbarbituric acid), pentobarbital (5-ethyl-5- [l -methylbutyl] -barbituric acid), secobarbital (5 - ally 1 - 5 - [1 - methylbutyl] barbituric acid), vinbarbital (5-ethyl-5- [l-methyl-1-butenyl] barbituric acid), butabarbital (S-ethyl-S-sec.-butylbarbituric acid) and mephobarbital ( 5-ethyl-1-methyl-5-phenylbarbituric acid).
Zur Herstellung der erfindungsgemäßen Molekülverbindungen kann man z. B. die Verbindung der Formel
I mit einer entsprechenden Barbitursäure vermischen und diese Mischung zum Schmelzen erhitzen
oder I mit einer Barbitursäure in Wasser, Methanol, Äthanol oder einem anderen organischen Lösungs-1
Mol
2MoI
3MoI
0,5 MolTo prepare the molecular compounds according to the invention you can, for. B. mix the compound of formula I with a corresponding barbituric acid and heat this mixture to melt or I with a barbituric acid in water, methanol, ethanol or another organic solution-1 mol
2MoI
3MoI
0.5 moles
1 Mol
2MoI
3MoI
0,5 Mol 1 mole
2MoI
3MoI
0.5 moles
1 Mol
2MoI
3MoI
0,5 Mol1 mole
2MoI
3MoI
0.5 moles
Barbital, 1 MolBarbital, 1 mole
desgl.the same
desgl.the same
desgl.the same
Allobarbital, 1 MqIAllobarbital, 1 MqI
desgl.the same
desgl.the same
desgl.the same
Cyclobarbital, 1 MolCyclobarbital, 1 mole
desgl.the same
desgl.the same
desgl.the same
Schmelzpunkt des Produkte·«Melting point of the product «
I ClI Cl
156 164
155 165
155 -164
155 -165
140-157
142-158
142 -157
143-158
162-168
161-168
160-167
161-167156 164
155 165
155 -164
155 -165
140-157
142-158
142 -157
143-158
162-168
161-168
160-167
161-167
Die abgeschiedenen Kristalle werden in einem Trockner bis zur Gewichtskonstanz getrocknet. Anschließend
wurde I gemäß den Vorschriften des japanischen amtlichen Arzneibuches bestimmt. Die Barbitursäuren
wurden nach der im amtlichen japanischen Arzneibuch beschriebenen Methode bestimmt. Die
Resultate der Bestimmung zeigten, daß immer Molekülverbindungen aus 1 Mol Barbitursäure und 2 Mol
I gebildet worden waren.
Zur weiteren Erläuterung der Herstellung der crfindungsgemäßen Verbindungen werden nachstehend
einige Beispiele gegeben.The deposited crystals are dried to constant weight in a dryer. Then, I was determined according to the prescriptions of the Japanese Pharmacopoeia. The barbituric acids were determined according to the method described in the official Japanese pharmacopoeia. The results of the determination showed that molecular compounds from 1 mole of barbituric acid and 2 moles of I had always been formed.
To further illustrate the preparation of the compounds according to the invention, some examples are given below.
Molekülverbindung aus 1 - Phenyl - 2,3 - dimethyl-4 - (aminoäthansulfonylamino) - pyrazolon - 5 und Barbital (5,5-Diäthylbarbitursäure)Molecular compound of 1 - phenyl - 2,3 - dimethyl-4 - (aminoethanesulfonylamino) - pyrazolone - 5 and Barbital (5,5-diethylbarbituric acid)
Zu Ig 1 - Phenyl - 2,3 - dimethyl - 4 - (aminoäthansulfonylamino)-pyrazolon-5 wurden 0,3 g Barbital und 30 ml Wasser hinzugefügt.To Ig 1 - phenyl - 2,3 - dimethyl - 4 - (aminoethanesulfonylamino) pyrazolone-5 0.3 g of barbital and 30 ml of water were added.
Die Mischung wurde auf direkter Flamme zur Herstellung einer Lösung erhitzt, auf 5 bis 10 ml konzentriert, filtriert und stehengelassen, wobei sich farblose Kristalle abschieden. Schmelzpunkt 155 bis 165 C, Ausbeute 1,1 g.The mixture was heated on a direct flame to make a solution, concentrated to 5 to 10 ml, filtered and allowed to stand and colorless crystals separated out. Melting point 155 to 165 ° C, yield 1.1 g.
Elementaranalyse: (2 · C13H18O3N4S) (C8H12O3N2):
Errechnet ... N 17,40%;
gefunden ... N 17,44%.Elemental Analysis: (2 · C 13 H 18 O 3 N 4 S) (C 8 H 12 O 3 N 2 ): Calculated ... N 17.40%;
found ... N 17.44%.
33
Molekülverbindung aus l-Phenyl-2,3-dimeihyl-4-{aminoäthansulfonylarnino)-pyrazolon-5 und Allobarbital (5,5-Diallylbarbitursäure)Molecular compound of l-phenyl-2,3-dimethyl-4- (aminoethanesulfonylamino) -pyrazolon-5 and allobarbital (5,5-diallylbarbituric acid)
Zu 3 g 1 - Phenyl - 2,3 - dimethyl - 4 - (aminoäthansulfonylamino) - pyrazolon - 5 und 2 g Allobarbital wurden 100 ml Wasser hinzugefügt und bis zur Lösung erhitzt. Die erhaltene Lösung wurde auf etwa 40 ml konzentriert, filtriert und stehengelassen, wobei sich farblose Kristalle abschieden. Schmelzpunkt 142 bis 158" C, Ausbeute 3,1 g.To 3 g of 1 - phenyl - 2,3 - dimethyl - 4 - (aminoethanesulfonylamino) - Pyrazolon - 5 and 2 g of allobarbital were added to 100 ml of water and until dissolved heated. The resulting solution was concentrated to about 40 ml, filtered and allowed to stand with colorless crystals separate. Melting point 142 to 158 "C, yield 3.1 g.
Elementaranalyse: (2 -C13H18O3N4S) (C10H12O3N2):
Errechnet ... N 16,90%;
gefunden .... N 16,91%.Elemental Analysis: (2 -C 13 H 18 O 3 N 4 S) (C 10 H 12 O 3 N 2 ): Calculated ... N 16.90%;
found .... N 16.91%.
Elementaranalyse: (2 - C13H18O3N4S) (C12H111O3N2):
Errechnet ... N 16,34%:
gefunden .... N 16,37%.Elemental analysis: (2 - C 13 H 18 O 3 N 4 S) (C 12 H 111 O 3 N 2 ):
Calculated ... N 16.34%:
found .... N 16.37%.
Zum Nachweis der fortschrittlichen Eigenschaften der erfindungsgemäßen Molekülverbindungen wurde die analgetische Wirkung mit Hilfe der Haffner-Methode im Vergleich zur Standard-Verbindung Aminophenazon geprüft. Als Versuchstiere wurden männliche Mäuse der »dd-K-pure strain« (I2g Körpergewicht) verwendet. Es wurden je IO Mäuse als eine Gruppe im Test eingesetzt. Nachstehende Tabelle zeig! das Ergebnis:To demonstrate the advanced properties of the molecular compounds according to the invention was the analgesic effect with the help of the Haffner method compared to the standard compound aminophenazone checked. Male mice of the "dd-K-pure strain" (I2g body weight) were used as test animals used. Each 10 mice were used as one group in the test. Table below show! the result:
"5"5
Molckülverbindung aus 1 - Phenyl - 2,3 - dimethyl-4 - (aminoäthansulfonylamino) - pyrazolon - 5 und Cyclobarbital (SfJ-Cyclohexenylj-S-athyl-barbitursäure) Molecular compound from 1 - phenyl - 2,3 - dimethyl-4 - (aminoethanesulfonylamino) - pyrazolone - 5 and Cyclobarbital (SfJ-Cyclohexenylj-S-ethyl-barbituric acid)
3 g 1 - Phenyl - 2,3 - dimethyl - 4 - (aminoäthansulfonylamino) - pyrazolon - 5 und 1,1 g Cyclobarbiial wurden gemeinsam in 100 ml Wasser unter Erhitzen aufgelöst und die Lösung auf etwa 50 ml konzentriert. Es wurde filtriert und das Filtrat stehengelassen, wobei sich farblose Kristalle abschieden. Schmelzpunkt 161 bis 168 C, Ausbeute 3 g.3 g 1 - phenyl - 2,3 - dimethyl - 4 - (aminoethanesulfonylamino) - Pyrazolon - 5 and 1.1 g Cyclobarbiial were mixed together in 100 ml of water while heating dissolved and the solution concentrated to about 50 ml. It was filtered and the filtrate left to stand, whereby colorless crystals separate. Melting point 161 up to 168 C, yield 3 g.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19681813275 DE1813275C3 (en) | 1968-12-04 | Molecular compounds from 1-phenyl-2,3-dimethyl-4- (aminoethanesulfonylamino) -pyrazolon-5 and barbituric acids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19681813275 DE1813275C3 (en) | 1968-12-04 | Molecular compounds from 1-phenyl-2,3-dimethyl-4- (aminoethanesulfonylamino) -pyrazolon-5 and barbituric acids |
Publications (3)
Publication Number | Publication Date |
---|---|
DE1813275A1 DE1813275A1 (en) | 1970-06-25 |
DE1813275B2 DE1813275B2 (en) | 1975-11-13 |
DE1813275C3 true DE1813275C3 (en) | 1976-06-24 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2228363A1 (en) | 1,4-DIHYDROPYRIDINE, METHOD FOR MANUFACTURING AND USE AS A MEDICINAL PRODUCT | |
DE1813275C3 (en) | Molecular compounds from 1-phenyl-2,3-dimethyl-4- (aminoethanesulfonylamino) -pyrazolon-5 and barbituric acids | |
DE2022656C3 (en) | 2- (Nicotinoylaminoethanesulfonylamino) pyridine | |
DE3039997A1 (en) | PHOSPHONOHYDROXYACETONITRILE, A METHOD FOR THE PRODUCTION THEREOF AND ITS USE AS AN INTERMEDIATE PRODUCT FOR THE PRODUCTION OF MEDICINAL PRODUCTS | |
DE1813275B2 (en) | Molecular compounds from 1-phenyl-2,3-dimethyl-4- (aminoethanesulfonylamino) -pyrazolon-5 and barbituric acids | |
DE1817958C3 (en) | Molecular compounds from aminoethanesulfonyl-p-phenetidine and barbituric acids | |
DE2512702C2 (en) | Substituted 1-amino-3-phenyl-indoles, their salts and process for their preparation | |
DE2166270B2 (en) | Nicotinoylaminoethanesulfonyl-2amino-thiazole | |
DE1817958B2 (en) | MOLECULAR COMPOUNDS OF AMINOETHANESULFONYL-P-PHENETIDINE AND BARBITURIC ACIDS | |
DE2008332C3 (en) | 2-methyl-S-methoxy-3-indolylacetohydroxamic acids, processes for their preparation and pharmaceuticals containing these compounds | |
DE2122070A1 (en) | 1 Veratryl 4 methyl 5 ethyl 7,8 dimethoxy 2,3 diazabicyclo square brackets to 5,4,0 square brackets to undeca pentaen (1,3,6,8,10) and its use | |
DE2065698B2 (en) | Process for the preparation of 2-isopropyl-6-methyl-4 (3H) -pyrimidone | |
DE921148C (en) | Process for the preparation of a condensation product from a p-aminobenzenesulfonamidopyrimidine, cinnamaldehyde and alkali bisulfite | |
DE1620301A1 (en) | Process for the preparation of 2-substituted cycloheptimidazole derivatives | |
AT158301B (en) | Process for the production of vitamin B1. | |
CH639959A5 (en) | 2,4-DIAMINO-5-THIOBENZYLPYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS. | |
DE515092C (en) | Process for the preparation of salts of choline | |
DE1924174C3 (en) | Magnesium Orotate Glycinate | |
DE1593832C3 (en) | Process for the production of Calcium DL Pantothenate | |
DE1620490C (en) | Pyrazolone (5) derivatives and a process for their preparation | |
DE1543295C3 (en) | N-substituted anthranilic acids, their salts, processes for the preparation of these compounds and medicaments containing these compounds | |
DE1445142C3 (en) | 2- (Benzolsurfonamido) -5-methoxyethoxypyrimidine derivatives | |
AT151657B (en) | Process for the preparation of formaldehyde sodium sulfoxylates from arsenobenzene compounds. | |
AT213896B (en) | Process for the preparation of new, basic substituted thioethers of pyrimidines | |
DE853167C (en) | Process for the preparation of pyrrolidine-acylaminobenzolar compounds |